Polyvalent dendrimer glucosamine conjugates prevent scar tissue formation

Nature Biotechnology

Volumn 22, Issue 8, 2004, Pages 977-984

  Shaunak, Sunil ^a   Thomas, Sharyn ^a   Gianasi, Elisabetta ^a   Godwin, Antony ^b   Jones, Emma ^c   Teo, Ian ^a   Mireskandari, Kamiar ^c   Luthert, Philip ^c   Duncan, Ruth ^d   Patterson, Steve ^e   Khaw, Peng ^c   Brocchini, Steve ^b  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d CARDIFF UNIVERSITY   (United Kingdom)

^e CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINES; SCAR TISSUE;

AMINES; GLUCOSE; SACCHARIFICATION; SOLUBILITY; SYNTHESIS (CHEMICAL); TISSUE;

DENDRIMERS;

B7 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; CHEMOKINE; DENDRIMER; DENDRIMER GLUCOSAMINE; DENDRIMER GLUCOSAMINE 6 SULFATE; FIBROBLAST GROWTH FACTOR 2; GLUCOSAMINE; GLUCOSAMINE SULFATE; INTERLEUKIN 1BETA; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MATRIGEL; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DISEASE MODEL; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENDOTHELIUM CELL; FEMALE; FILTERING OPERATION; GLAUCOMA; HUMAN; HUMAN CELL; IMMUNOMODULATION; MACROMOLECULE; MACROPHAGE; NONHUMAN; PLANKTON; PRIORITY JOURNAL; RABBIT; SCAR FORMATION; TREATMENT OUTCOME; UPREGULATION; VALIDATION PROCESS;

ANIMALS; CATARACT EXTRACTION; CELL LINE; CELL PROLIFERATION; CELLS, CULTURED; CHEMOKINES; CICATRIX; DENDRITIC CELLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; ENDOTHELIAL CELLS; GLUCOSAMINE; HUMANS; MACROMOLECULAR SUBSTANCES; NEOVASCULARIZATION, PATHOLOGIC; RABBITS; TREATMENT OUTCOME; WOUND HEALING;

ANIMALIA; ORYCTOLAGUS CUNICULUS;

EID: 3542993234     PISSN: 10870156     EISSN: None     Source Type: Journal    
DOI: 10.1038/nbt995     Document Type: Article

References (50)

1. Tomalia, D.A., Naylor, A.M. & Goddard, W.A. III. Starburst dendrimers: molecular level control of size, shape, surface chemistry, topology and flexibility from atoms to macroscopic matter. Angew. Chem. Int. Edit. 29, 138-175 (1990).
2. Esfand, R. & Tomalia, D.A. Laboratory synthesis of poly(amidoamine) (PAMAM) dendrimers. in Dendrimer and Other Dendritic Polymers (eds. Frechet, J.M.J. & Tomalia, D.A.) 587-604 (Wiley, New York, 2001).
3. Malik, N., Evagorou, E.G. & Duncan, R. Dendrimer-platinate: a novel approach to cancer chemotherapy. Anticancer Drugs 10, 767-776 (1999).
4. Zanini, D. & Roy, R. Practical synthesis of starburst PAMAM α-thiosialodendrimers for probing multivalent carbohydrate-lectin binding properties. J. Org. Chem. 63, 3486-3491 (1998).
5. Cloninger, M.J. Biological applications of dendrimers. Curr. Opin. Chem. Biol. 6, 742-748 (2002).
6. Thornton, M., Barkley, L. & Shaunak, S. The anti-Kaposi's sarcoma and anti-angiogenic activity of sulphated dextrins. Antimicrob. Agents Chemotherapy 43, 2528-2533 (1999).
7. Duncan, R. The dawning of polymer therapeutics. Nat. Rev. Drug Discov. 2, 347-360 (2003).
8. Roy, R. Recent developments in the rational design of multivalent glycoconjugates. Top. Curr. Chem. 187, 24-274 (1997).
9. Mammen, M., Choi, S.-K. & Whitesides, G.M. Polyvalent interactions in biological systems: implications for design and use of multivalent ligands and inhibitors. Angew. Chem. Int. Edit. 37, 2754-2794 (1998).
10. Roberts, J.C., Bhalgat, M.K. & Zera, R.T. Preliminary biological evaluation of polyamidoamine (PAMAM) starburst dendrimers. J. Biomed. Mater. Res. 30, 53-65 (1996).
11. Jevprasesphant, R., Penny, J., Attwood, D., McKeown, N.B. & D'Emmanuele, A. Engineering of dendrimer surfaces to enhance transepithelial transport and reduce cytotoxicity. Pharm. Res. 20, 1543-1550 (2003).
12. 125I-labelled polyamidoamine dendrimers in vivo. J. Controlled Release 65, 133-148 (2002).
13. Koyanagi, S., Tanigawa, N., Nakagawa, H., Soeda, S. & Shimeno, H. Oversulfation of fucoidan enhances its anti-angiogenic and anti-tumor activities. Biochem. Pharmacol. 65, 173-179 (2003).
14. Brandtzaeg, P. et al. Net inflammatory capacity of human septic shock plasma evaluated by a monocyte based target cell assay: identification of interleukin-10 as a major functional deactivator of human monocytes. J. Exp. Med. 184, 51-60 (1996).
15. Wang, Z.M., Liu, C. & Dziarski, R. Chemokines are the main pro-inflammatory mediators in human monocytes activated by Staphylococcus aureus, peptidoglycan, and endotoxin. J. Biol. Chem. 275, 20260-20267 (2000).
16. Le Naour, F. et al. Profiling changes in gene expression during differentiation and maturation of monocyte derived dendritic cells using both oligonucleotide microarrays and proteomics. J. Biol. Chem. 276, 17920-17931 (2001).
17. 2 antibody as a new postoperative anti-scaring agent in glaucoma surgery. Invest. Ophthalmol. Vis. Sci. 44, 3394-3401 (2003).
18. Khaw, P.T., Doyle, J.W., Sherwood, M.B., Smith, M.F. & McGorray, S. Effects of intraoperative 5-fluorouracil or mitomycin C on glaucoma filtration surgery in the rabbit. Ophthalmology 100, 367-372 (1993).
19. 2 monoclonal antibody-a new modulator of wound healing in trabeculectomy. Ophthalmology 109, 427-431 (2002).
20. Spinks, R.L., Baker, S.N., Jackson, A., Khaw, P.T. & Lemon, R.N. The problem of dural scaring: a solution using 5-fluorouracil. J. Neurophysiol. 90, 1324-1332 (2003).
21. The AGIS investigators. The advanced glaucoma intervention study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am. J. Ophthalmol. 130, 429-440 (2000).
22. Chang, L., Crowston, J.G., Cordeiro, M.F., Akbar, A.N. & Khaw, P.T. The role of the immune system in conjunctival wound healing after glaucoma surgery. Surv. Ophthalmol. 45, 49-68 (2000).
23. Wells, A.P., Cordeiro, M.F., Bunce, C. & Khaw, P.T. Cystic bleb formation and related complications in limbus versus fornix based conjunctival flaps in paediatric and young adult trabeculectomy with mitomycin-C. Ophthalmology 110, 2192-2197 (2003).
24. Flo, F.H. et al. Involvement of TLR2 and TLR4 in cell activation by mannuronic acid polymers. J. Biol. Chem. 277, 35489-35495 (2002).
25. Garcia-Ramallo, E. et al. Resident cell chemokine expression serves as the major mechanism for leucocyte recruitment during local inflammation. J. Immunol. 169, 6467-6473 (2002).
26. Sweeney, E.A., Lortat-Jacob, H., Priestley, G.V., Nakamoto, B. & Papayannopoulou, T. Sulfated polysaccharides increase plasma levels of SDF-1 in monkeys and mice: involvement in mobilization of stem/progenitor cells. Blood 99, 44-51 (2002).
27. Termeer, C. et al. Oligosaccharides of hyaluronan activate dendritic cells via toll-like receptor 4. J. Exp. Med. 195, 99-111 (2002).
28. Lehto, M. & Jarvinen, M. Collagen and glycosaminoglycan synthesis of injured gastrocnemius muscle in rat. Eur. Surg. Res. 17, 179-185 (1985).
29. Fukasawa, M., Bryant, S.M., Orita, H., Campeau, J.D. & DiZerega G.S. Modulation of proline and glucosamine incorporation into tissue repair cells by peritoneal macrophages. J. Surg. Res. 46, 166-171 (1989).
30. Schmidt, R.J., Spyratou, O. & Turner, T.D. Biocompatibility of wound management products: the effect of various monosaccharides on L929 and 2002 fibroblast cells in culture. J. Pharm. Pharmacol. 41, 781-784 (1989).
31. 14C]glucosamine to the rat. Pharmatherapeutica 3, 538-550 (1984).
32. Aghazadeh-Habashi, A., Sattari, S., Pasutto, F.M. & Jamali, F. Single dose pharmacokinetics and bioavailability of glucosamine in the rat. J. Pharm. Pharm. Sci. 5, 181-184 (2002).
33. Setnikar, I. & Rovati, L.C. Absorption, distribution, metabolism and excretion of glucosamine sulfate. Arzneimitteforschung 51, 699-725 (2001).
34. Hoshino, K. et al. TLR4 deficient mice are hyporesponsive to LPS: evidence for TLR4 as the LPS gene product. J. Immunol. 162, 3749-3752 (1999).
35. Takeuchi, O. et al. Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity 11, 443-451 (1999).
36. Gordon, S. Pattern recognition receptors: doubling up for the innate immune response. Cell 111, 927-930 (2002).
37. Paterson, H.M. et al. Injury primes the innate immune system for enhanced toll-like receptor reactivity. J. Immunol. 171, 1473-1483 (2003).
38. Gillitzer, R. & Goebeler, M. Chemokines in cutaneous wound healing. J. Leucocyte Biol. 69, 513-521 (2001).
39. Smiley, S.T., King, J.A. & Hancock, W.W. Fibrinogen stimulates macrophage chemokine secretion through TLR4. J. Immunol. 167, 2887-2894 (2001).
40. Tumpey, T.M. et al. Absence of MIP-1α prevents the development of blinding herpes stromal keratitis. J. Virol. 72, 3705-3710 (1998).
41. Pye, D.A., Vives, R.R., Turnbull, J.E., Hyde, P. & Gallagher, J.T. Heparan sulfate oligosaccharides require 6-O-sulfation for promotion of basic fibroblast growth factor mitogenic activity. J. Biol. Chem. 273, 22936-22942 (1998).
42. Lundin, L. et al. Selectively desulfated heparin inhibits fibroblast growth factor-induced mitogenicity and angiogenesis. J. Biol. Chem. 275, 24653-24660 (2000).
43. Schlessinger, J. et al. Crystal structure of a ternary FGF-FGFR-heparin compex reveals a dual role for heparin in FGFR binding and dimerization. Mol. Cell 6, 743-750 (2000).
44. Li, A., Dubey, S., Varney, M.L., Dave, B.J. & Singh, R.K. IL-18 directly enhanced endothelial cell survival, proliferation, and matrix metalloprotenases production and regulated angiogenesis. J. Immunol. 170, 3369-3376 (2003).
45. Girard, J.P. & Springer, T.A. High endothelial venules: specialised endothelium for lymphocyte migration. Immunol. Today 16, 449-457 (1995).
46. Choy, E.H. & Panayi, G.S. Cytokine pathways and joint inflammation in rheumatoid arthritis. N. Engl. J. Med. 344, 907-916 (2001).
47. Johnson, G.B., Brunn, G.J. & Platt, J.L. An endogenous pathway to systemic inflammatory response syndrome (SIRS)-like reactions through Toll-like receptor 4. J. Immunol. 172, 20-24 (2004).
48. Sgouras, D. & Duncan, R. Methods for the evaluation of biocompatibility of soluble synthetic polymers which have potential for biomedical use. 1. Use of tetrazolium-based colorimetric assay as a preliminary screen for evaluation of in vitro cytotoxicity. J. Mater. Sci. Mater. Med. 1, 61-68 (1990).
49. Kubota, Y., Kleinman, H.K., Martin, G.R. & Lawley, T.J. Role of laminin and basement membrane in the morphological differentiation of human endothelial cells into capillary-like structures. J. Cell Biol. 107, 1589-1598 (1988).
50. Cordeiro, M.F., Gay, J.A., & Khaw, P.T. Human anti-TGF-β antibody: a new glaucoma anti-scarring agent. Invest. Ophthalmol. Vis. Sci. 40, 2225-2234 (1999).